B-Cell Maturation Antigen (BCMA)

Overview

B-Cell Maturation Antigen (BCMA) is a protein that may be found on the surface of myeloma cells. BCMA may be used as a target to help treatments find and destroy myeloma cells.

Explore Tags

Myeloma Treatments

The following is a listing of myeloma treatments associated with this tag.

All Treatments

View all treatments in development for myeloma patients around the US.

Verified Belantamab Mafodotin
Belantamab Mafodotin

Belantamab Mafodotin (formerly GSK2857916) is an antibody-drug conjugate (ADC) directed against the B-cell maturation antigen (BCMA).

Verified Descartes-08
Descartes-08

Descartes-08 is a cell therapy wherein T-cells are modified to attack myeloma cells. To modify the cells, new instructions (called RNA) are inserted into the T-cells.

Verified SEA-BCMA
SEA-BCMA

SEA-BCMA is a new antibody targeting the B-cell maturation antigen (BCMA) protein and being tested in multiple myeloma.

Verified TNB-383B
TNB-383B

TNB-383B is a bi-specific antibody, meaning that it interacts with two molecules in your body. One molecule is called B-Cell Maturation Antigen (BMCA) and is found on your multiple myeloma cells. The second is called CD3 and is present on your killer T-cells.

SparkCures Verified Accurate, up-to-date information. Learn more


Early Relapse Multiple Myeloma

The following is a listing of treatments in development for patients with multiple myeloma who have received one to two prior lines of therapy.

Verified Belantamab Mafodotin
Belantamab Mafodotin

Belantamab Mafodotin (formerly GSK2857916) is an antibody-drug conjugate (ADC) directed against the B-cell maturation antigen (BCMA).

Verified Descartes-08
Descartes-08

Descartes-08 is a cell therapy wherein T-cells are modified to attack myeloma cells. To modify the cells, new instructions (called RNA) are inserted into the T-cells.

Verified TNB-383B
TNB-383B

TNB-383B is a bi-specific antibody, meaning that it interacts with two molecules in your body. One molecule is called B-Cell Maturation Antigen (BMCA) and is found on your multiple myeloma cells. The second is called CD3 and is present on your killer T-cells.

SparkCures Verified Accurate, up-to-date information. Learn more


Late Relapse Multiple Myeloma

The following is a listing of treatments in development for patients with multiple myeloma who have received three or more prior lines of therapy.

Verified Belantamab Mafodotin
Belantamab Mafodotin

Belantamab Mafodotin (formerly GSK2857916) is an antibody-drug conjugate (ADC) directed against the B-cell maturation antigen (BCMA).

Verified Descartes-08
Descartes-08

Descartes-08 is a cell therapy wherein T-cells are modified to attack myeloma cells. To modify the cells, new instructions (called RNA) are inserted into the T-cells.

Verified SEA-BCMA
SEA-BCMA

SEA-BCMA is a new antibody targeting the B-cell maturation antigen (BCMA) protein and being tested in multiple myeloma.

Verified TNB-383B
TNB-383B

TNB-383B is a bi-specific antibody, meaning that it interacts with two molecules in your body. One molecule is called B-Cell Maturation Antigen (BMCA) and is found on your multiple myeloma cells. The second is called CD3 and is present on your killer T-cells.

SparkCures Verified Accurate, up-to-date information. Learn more


Myeloma Clinical Trials

The following is a listing of myeloma clinical trials associated with this tag.

All Clinical Trials

View all active clinical trials around the US.

SparkCures Verified Accurate, up-to-date information. Learn more


Early Relapse Multiple Myeloma

The following is a listing of clinical trials for patients with multiple myeloma who have received one to two prior lines of therapy.

SparkCures Verified Accurate, up-to-date information. Learn more


Late Relapse Multiple Myeloma

The following is a listing of clinical trials for patients with multiple myeloma who have received three or more prior lines of therapy.

SparkCures Verified Accurate, up-to-date information. Learn more


Smoldering Myeloma
Monoclonal Gammopathy of Undetermined Significance (MGUS)
Myeloma Tags

The following is a listing of myeloma tags that are associated with this tag.

Antibody Drug Conjugate

Antibody Drug Conjugates (ADC) work by combining a chemotherapy drug with a monoclonal antibody. This allows the chemotherapy drug to target a specific cancer cell while limiting the damage to healthy cells.

Bispecific Antibody

A bispecific antibody is a drug that has been designed to simultaneously target two different proteins. Both targets may be expressed by a cancer cell, or these drugs may target both cancer cells and T cells.

Bispecific T Cell Engager (BiTE)

BiTEs are a type of immunotherapy. They consist of monoclonal antibodies that can target and bind to both myeloma cells and T Cells.

CAR T Cell

CAR T Cell therapy is a new way to treat multiple myeloma using your own immune system to target and destroy cancer cells.

Monoclonal Antibody

Monoclonal antibodies are large, y-shaped, man-made proteins. They are able to target cancer cells by finding and attaching to unique proteins found on the cell's surface.

Resources